CA3202328A1 - Chemical compounds useful for inhibiting nav1.8 voltage-gated sodium channels and treating nav1.8 mediated diseases - Google Patents
Chemical compounds useful for inhibiting nav1.8 voltage-gated sodium channels and treating nav1.8 mediated diseasesInfo
- Publication number
- CA3202328A1 CA3202328A1 CA3202328A CA3202328A CA3202328A1 CA 3202328 A1 CA3202328 A1 CA 3202328A1 CA 3202328 A CA3202328 A CA 3202328A CA 3202328 A CA3202328 A CA 3202328A CA 3202328 A1 CA3202328 A1 CA 3202328A1
- Authority
- CA
- Canada
- Prior art keywords
- pain
- compound
- pharmaceutically acceptable
- acceptable salt
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063127341P | 2020-12-18 | 2020-12-18 | |
| US63/127,341 | 2020-12-18 | ||
| PCT/EP2021/086101 WO2022129283A1 (en) | 2020-12-18 | 2021-12-16 | Chemical compounds useful for inhibiting nav1.8 voltage-gated sodium channels and treating nav1.8 mediated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3202328A1 true CA3202328A1 (en) | 2022-06-23 |
Family
ID=79025144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3202328A Pending CA3202328A1 (en) | 2020-12-18 | 2021-12-16 | Chemical compounds useful for inhibiting nav1.8 voltage-gated sodium channels and treating nav1.8 mediated diseases |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP4262978A1 (https=) |
| JP (1) | JP2024502231A (https=) |
| KR (1) | KR20230121827A (https=) |
| CN (1) | CN116710463A (https=) |
| AU (1) | AU2021403606B2 (https=) |
| CA (1) | CA3202328A1 (https=) |
| CL (1) | CL2023001750A1 (https=) |
| CO (1) | CO2023008049A2 (https=) |
| IL (1) | IL303795A (https=) |
| MX (1) | MX2023007244A (https=) |
| PH (1) | PH12023551406A1 (https=) |
| SA (1) | SA523441263B1 (https=) |
| WO (1) | WO2022129283A1 (https=) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2931550C (en) * | 2013-12-13 | 2023-09-26 | Vertex Pharmaceuticals Incorporated | Prodrugs of pyridone amides useful as modulators of sodium channels |
| GB201322602D0 (en) * | 2013-12-19 | 2014-02-05 | Almac Discovery Ltd | Pharmaceutical compounds |
| EP3625214B1 (en) * | 2017-05-16 | 2022-07-06 | Vertex Pharmaceuticals Incorporated | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels |
| MX2021015605A (es) * | 2019-06-27 | 2022-02-16 | Glaxosmithkline Ip Dev Ltd | Compuestos 2,3-dihidroquinazolin como inhibidores nav1.8. |
-
2021
- 2021-12-16 EP EP21831047.2A patent/EP4262978A1/en active Pending
- 2021-12-16 WO PCT/EP2021/086101 patent/WO2022129283A1/en not_active Ceased
- 2021-12-16 JP JP2023536951A patent/JP2024502231A/ja not_active Ceased
- 2021-12-16 KR KR1020237023878A patent/KR20230121827A/ko active Pending
- 2021-12-16 MX MX2023007244A patent/MX2023007244A/es unknown
- 2021-12-16 AU AU2021403606A patent/AU2021403606B2/en active Active
- 2021-12-16 PH PH1/2023/551406A patent/PH12023551406A1/en unknown
- 2021-12-16 IL IL303795A patent/IL303795A/en unknown
- 2021-12-16 CN CN202180085151.XA patent/CN116710463A/zh active Pending
- 2021-12-16 CA CA3202328A patent/CA3202328A1/en active Pending
-
2023
- 2023-06-15 CL CL2023001750A patent/CL2023001750A1/es unknown
- 2023-06-18 SA SA523441263A patent/SA523441263B1/ar unknown
- 2023-06-21 CO CONC2023/0008049A patent/CO2023008049A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023007244A (es) | 2023-06-29 |
| CL2023001750A1 (es) | 2024-01-19 |
| CO2023008049A2 (es) | 2023-06-30 |
| JP2024502231A (ja) | 2024-01-18 |
| SA523441263B1 (ar) | 2025-01-07 |
| AU2021403606B2 (en) | 2024-11-14 |
| KR20230121827A (ko) | 2023-08-21 |
| PH12023551406A1 (en) | 2024-01-22 |
| IL303795A (en) | 2023-08-01 |
| AU2021403606A1 (en) | 2023-06-22 |
| WO2022129283A1 (en) | 2022-06-23 |
| EP4262978A1 (en) | 2023-10-25 |
| CN116710463A (zh) | 2023-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7701880B2 (ja) | ＮａＶ１．８阻害剤としての２，３－ジヒドロキナゾリン化合物 | |
| CN115135650A (zh) | 作为kras抑制剂的吡啶并嘧啶衍生物 | |
| JP2021500330A (ja) | Ｐａｄ阻害剤としてのイミダゾ−ピリジン化合物 | |
| EA034931B1 (ru) | Индолкарбоксамидные соединения | |
| JPWO2015163435A1 (ja) | 新規２−アミノ−ピリジン及び２−アミノ−ピリミジン誘導体及びその医薬用途 | |
| CN116601153B (zh) | 作为nav1.8抑制剂的含氮2,3-二氢喹唑啉酮化合物 | |
| KR20220105425A (ko) | 티아졸로피리딘 또는 이의 약학적으로 허용 가능한 염 및 이의 용도 | |
| JP2025522369A (ja) | Ｎａｖ１．８阻害剤としての縮合含窒素２，３－ジヒドロキナゾリノン化合物 | |
| JP2017078039A (ja) | 新規２−アミノ−ピリジン又は２−アミノ−ピリミジン誘導体を有効成分として含有する医薬組成物 | |
| US20250084112A1 (en) | Chemical Compounds Useful for Inhibiting Nav1.8 Voltage-Gated Sodium Channels and Treating Nav1.8 Mediated Diseases | |
| AU2021403606B2 (en) | Chemical compounds useful for inhibiting nav1.8 voltage-gated sodium channels and treating nav1.8 mediated diseases | |
| US20230416287A1 (en) | Chemical Compounds | |
| TWI914378B (zh) | 作為ａｌｋ５抑制劑之嗒𠯤基胺基衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241206 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241206 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241206 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED Effective date: 20250422 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R107 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRECT APPLICANT REQUEST RECEIVED Effective date: 20250509 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251124 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251124 |
|
| R13 | Change to the name of applicant or owner recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R13-R109 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRECT APPLICANT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260408 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260408 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260408 |